HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
June 21, 2018
-
TRENDS Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
-
REGULATORY PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
June 19, 2018
-
ORGANIZATION Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
June 18, 2018
-
REGULATORY Authorized Generics for Aimix, Cravit IV Join NHI Price List
June 15, 2018
-
REGULATORY Chuikyo Agrees on No Willing-to-Pay Cost Survey before CEA Rollout; Experts Say Pilot ICER Thresholds “Justifiable”
June 14, 2018
-
REGULATORY Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
June 14, 2018
-
REGULATORY Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
June 13, 2018
-
REGULATORY PMDA to Promote Development of Next-Generation Drugs by Improving Its Science Level in Drug Evaluation
June 13, 2018
-
BUSINESS Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
-
REGULATORY MHLW Panel Gives Thumbs-Up for Entyvio, Official Nod Expected This Month
June 11, 2018
-
BUSINESS Bayer Establishes Asia’s 1st “CoLaborator” in Kobe for Use by Startups
June 8, 2018
-
REGULATORY AMED Discloses Individual R&D Project Funding; 31 Receive Funding of Over 1 Billion Yen
June 7, 2018
-
REGULATORY Japan Eyes Economic Assessments for New Drug Listing: Draft Honebuto Paper
June 6, 2018
-
ACADEMIA MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
-
BUSINESS FY2017 Earnings Roundup - 2: Global Brands Gaining Further Traction, Some Notch Better-than-Expected Growth
June 5, 2018
-
BUSINESS FY2017 Earnings Roundup - 1: Major Japan Makers Braced for Gloomier Year Ahead at Home, See 4.4% Dip
June 4, 2018
-
BUSINESS Japan Drug Makers See Rising Overseas Sales Ratio amid Uphill Battle at Home: Tally
June 1, 2018
-
TRENDS Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
May 31, 2018
-
REGULATORY Japan’s First Biosimilars for Enbrel, Herceptin Added to NHI Price List
May 30, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
